These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 9809468)
1. Analogs of staurosporine: potential anticancer drugs? Gescher A Gen Pharmacol; 1998 Nov; 31(5):721-8. PubMed ID: 9809468 [TBL] [Abstract][Full Text] [Related]
2. Characterisation of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine. Courage C; Bradder SM; Jones T; Schultze-Mosgau MH; Gescher A Int J Cancer; 1997 Nov; 73(5):763-8. PubMed ID: 9398059 [TBL] [Abstract][Full Text] [Related]
4. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation. Akiyama T; Sugiyama K; Shimizu M; Tamaoki T; Akinaga S Jpn J Cancer Res; 1999 Dec; 90(12):1364-72. PubMed ID: 10665655 [TBL] [Abstract][Full Text] [Related]
5. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation. Courage C; Budworth J; Gescher A Br J Cancer; 1995 Apr; 71(4):697-704. PubMed ID: 7710931 [TBL] [Abstract][Full Text] [Related]
6. Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole. Akiyama T; Shimizu M; Okabe M; Tamaoki T; Akinaga S Anticancer Drugs; 1999 Jan; 10(1):67-78. PubMed ID: 10194549 [TBL] [Abstract][Full Text] [Related]
7. UCN-01 (7-hydroxystaurosporine) inhibits the growth of human breast cancer xenografts through disruption of signal transduction. Koh J; Kubota T; Migita T; Abe S; Hashimoto M; Hosoda Y; Kitajima M Breast Cancer; 2002; 9(1):50-4. PubMed ID: 12196722 [TBL] [Abstract][Full Text] [Related]
8. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells. Budworth J; Davies R; Malkhandi J; Gant TW; Ferry DR; Gescher A Br J Cancer; 1996 May; 73(9):1063-8. PubMed ID: 8624264 [TBL] [Abstract][Full Text] [Related]
9. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1). Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646 [TBL] [Abstract][Full Text] [Related]
11. Decrease in susceptibility toward induction of apoptosis and alteration in G1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-Hydroxystaurosporine). Sugiyama K; Akiyama T; Shimizu M; Tamaoki T; Courage C; Gescher A; Akinaga S Cancer Res; 1999 Sep; 59(17):4406-12. PubMed ID: 10485490 [TBL] [Abstract][Full Text] [Related]
13. Modulation of apoptosis in rat thymocytes by analogs of staurosporine: lack of direct association with inhibition of protein kinase C. Harkin ST; Cohen GM; Gescher A Mol Pharmacol; 1998 Oct; 54(4):663-70. PubMed ID: 9765509 [TBL] [Abstract][Full Text] [Related]
14. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Utz I; Hofer S; Regenass U; Hilbe W; Thaler J; Grunicke H; Hofmann J Int J Cancer; 1994 Apr; 57(1):104-10. PubMed ID: 7908658 [TBL] [Abstract][Full Text] [Related]
15. A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti- ras peptide. Way D; Smith S; Sivendran S; Chie L; Kanovsky M; Brandt-Rauf PW; Chung DL; Michl J; Pincus MR Cancer Chemother Pharmacol; 2002 Jun; 49(6):429-37. PubMed ID: 12107546 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter. Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263 [TBL] [Abstract][Full Text] [Related]
18. Cellular relocalisation of protein kinase C-theta caused by staurosporine and some of its analogues. Jones T; Courage C; Hubbard A; Gescher A Biochem Pharmacol; 1997 May; 53(10):1413-8. PubMed ID: 9260867 [TBL] [Abstract][Full Text] [Related]
19. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Akinaga S; Nomura K; Gomi K; Okabe M Cancer Chemother Pharmacol; 1994; 33(4):273-80. PubMed ID: 7506638 [TBL] [Abstract][Full Text] [Related]
20. UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice. Redkar AA; Meadows GG; Daoud SS Int J Oncol; 2001 Jul; 19(1):193-9. PubMed ID: 11408942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]